首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

2024877

脫髮症治療市場規模、佔有率、趨勢和預測：按藥物類型、適應症、性別、給藥途徑、配銷通路和地區分類，2026-2034 年

Alopecia Treatment Market Size, Share, Trends and Forecast by Drug Type, Indication, Gender, Route of Administration, Distribution Channel, and Region, 2026-2034

出版日期: 2026年04月01日 | 出版商:

IMARC | 英文 148 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2025年全球脫髮症治療市場規模為35億美元。展望未來，IMARC Group預測，該市場將在2026年至2034年間以3.74%的複合年成長率成長，到2034年達到50億美元。目前，北美市場主導地位，預計2025年將佔據超過38.34%的市場。推動該市場成長的因素包括脫髮症的上升、醫療保健領域的大量投資以及消費者日益增強的美容意識，這凸顯了外表和自我護理的重要性。

脫髮症治療市場正經歷強勁成長，這主要得益於人們對脫髮症的認知不斷提高以及醫療和美容解決方案的進步。老齡化、荷爾蒙失衡、壓力和自體免疫疾病等因素導致脫髮症盛行率不斷上升，顯著推動了對有效治療方法的需求。再生醫學、幹細胞療法和先進藥物等治療方法的創新正在擴大市場規模。此外，社群媒體影響力的日益增強和可支配收入的增加也推動了消費者對專業治療的需求，進一步促進了市場成長。同時，電子商務平台的擴張也使脫髮症治療更加便捷，尤其是在發展中地區，促進了全球市場的擴張。

在美國，脫髮症治療市場的發展主要得益於人們對脫髮的高度關注以及對先進醫療解決方案的強勁需求。完善的醫療基礎設施為創新脫髮症治療方法的研發和推廣提供了支持，包括口服和外用療法。例如，2024年9月，總部位於美國的製藥公司Amplifica宣布了其首個針對男性型脫髮症的新型皮內注射療法AMP-303的人體臨床試驗取得了令人鼓舞的結果。研究表明，AMP-303在單次治療後可顯著增加頭髮密度和粗度，展現出持續的療效和卓越的安全性。此外，市場也受惠於對旨在發現新的生髮方案的研發投入。消費者對非侵入性和美容解決方案的日益偏好，以及專業皮膚科診所的普及，使美國成為脫髮症治療的主要市場。策略合作和新產品的推出進一步鞏固了其成長勢頭。

脫髮症治療市場趨勢：

脫髮症盛行率增加

雄性脫髮症是一種常見的脫髮症類型，男女均可受其影響。根據2023年發表在《美國皮膚病學會國際雜誌》（JAAD）上的一項研究，脫髮症的影響因種族和性別而異，影響15%的停經後女性和超過50%的老年男性，而頭髮稀疏最早可能在青春期就開始出現。此外，推動脫髮症治療市場發展的關鍵因素之一是遺傳性疾病（如脫髮症和脫髮症的上升。根據美國國家脫髮症基金會估計，美國有670萬人患有或面臨脫髮症。目前，美國約有70萬人患有脫髮症。此外，脫髮症影響全球約2%的人口，凸顯了這種導致脫髮的疾病的廣泛流行。根據對脫髮症治療市場的概述，隨著越來越多的人意識到這種疾病並尋求有效的治療方法，該行業的需求正在成長。因此，醫療技術的進步和可用治療方法的多樣化促使人們尋求醫療幫助以促進頭髮再生，從而推動了脫髮症治療市場的顯著成長。

醫療保健支出增加

全球醫療保健支出不斷成長是推動脫髮症治療市場成長的關鍵因素。報告顯示，2020年全球醫療保健支出平均成長了21%。到2021年，這一數字進一步攀升，與2019年相比增幅高達25%。此外，2021年至2022年，大多數主要可比較國家的人均醫療保健支出均有所成長。美國、澳洲（2.4%）、加拿大（0.7%）和英國（0.5%）的人均醫療保健支出均實現了2.9%的溫和成長。在有數據可查的國家中，比利時的增幅最大，2021年至2022年人均醫療保健支出增加了9.6%。已開發國家的醫療保健支出成長尤其顯著，顯示人們強烈願意為脫髮症治療等尖端醫療服務付費。因此，經濟實力的增強和可支配收入的增加，使得更多人能夠獲得脫髮症治療方案，從而促進了市場成長。

人們對美的意識日益增強

此外，全球對個人形象和美學的日益關注也顯著推動了脫髮症治療市場的擴張。國際毛髮修復外科學會 (ISHRS) 的一項調查顯示，ISHRS 會員平均治療了 165 例手術患者和 396 例非手術患者。 2021 年，約三分之二 (65%) 的 ISHRS 會員進行了 0-199 例植髮手術，平均每位會員完成 179 例手術。同時，78% 的 ISHRS 會員進行了 0-19 例植髮手術。 2021 年，會員平均每月完成 14 例植髮手術。這一成長趨勢顯示人們對個人形象的關注度不斷提高，社群媒體的影響和理想美學標準的呈現進一步強化了這一趨勢。為了符合公認的美學標準和承受文化壓力，人們對有效的植髮治療方法產生了巨大的需求。因此，隨著越來越多的人尋求改善自身形象和解決脫髮問題的方法，脫髮症治療市場正在擴大。

市場結構
大公司
主要公司簡介
- Aclaris Therapeutics Inc.
- Cellmid Limited
- Cipla Limited
- Dr. Reddy's Laboratories Ltd.
- GlaxoSmithKline plc
- HCell Inc.
- Johnson & Johnson
- Merck & Co. Inc.
- Pfizer Inc.
- Taisho Pharmaceutical Holdings Co. Ltd
- Teva Pharmaceutical Industries Ltd.

簡介目錄

Product Code: SR112026A4147

The global alopecia treatment market size was valued at USD 3.5 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 5.0 Billion by 2034, exhibiting a CAGR of 3.74% from 2026-2034. North America currently dominates the market, holding a market share of over 38.34% in 2025. The market is driven by the increasing prevalence of alopecia, significant investment in healthcare expenditure, and the growing aesthetic consciousness among consumers highlighting the importance of appearance and self-care.

The alopecia treatment market is experiencing robust growth, driven by rising awareness about hair loss conditions and advancements in medical and cosmetic solutions. Increasing prevalence of alopecia, fueled by factors such as aging, hormonal imbalances, stress, and autoimmune disorders, has significantly boosted demand for effective treatment options. Innovations in therapeutic approaches, including regenerative medicine, stem cell therapy, and advanced pharmaceuticals, have expanded the market's scope. Moreover, the growing influence of social media and increasing disposable income have encouraged consumers to seek professional treatments, further driving market growth. Additionally, the expansion of e-commerce platforms has made alopecia treatments more accessible, especially in developing regions, contributing to the market's global expansion.

In the United States, the alopecia treatment market is propelled by a high awareness level and strong demand for advanced medical solutions. A well-established healthcare infrastructure supports the development and adoption of innovative treatments, such as oral and topical therapies for alopecia. For instance, in September 2024, Amplifica, a U.S. based pharmaceutical company, announced promising results from its first-in-human trial of AMP-303, a novel intradermal treatment for androgenetic alopecia. The study showed AMP-303 significantly increased hair density and thickness after one treatment, with durable effects and a strong safety profile. The market also benefits from significant investments in research and development, aiming to discover novel solutions for hair regrowth. Moreover, rising consumer preference for non-invasive and aesthetic solutions, alongside the availability of specialized dermatology clinics, positions the U.S. as a leading market for alopecia treatments. Besides this, strategic collaborations and product launch further strengthen its growth trajectory.

ALOPECIA TREATMENT MARKET TRENDS:

Increasing Prevalence of Alopecia

Androgenetic alopecia is a prevalent form of patterned hair loss that is seen in men and women. As per the Journal of the American Academy of Dermatology International (JAAD) published survey in 2023, alopecia affects different racial and gender groups differently, 15% of postmenopausal women and over 50% of elderly males experience it, while thinning hair can begin as early as puberty. Apart from that, one of the crucial factors driving the development of the alopecia treatment market is the increasing incidence of alopecia, a hereditary condition, and disorders such as alopecia areata. The National Alopecia Areata Foundation estimates that 6.7 million Americans and about 160 million individuals worldwide have alopecia areata or may acquire it. Currently, alopecia areata affects about 700,000 persons in the United States. Furthermore, alopecia areata affects about 2% of people worldwide, underscoring the disorder's widespread prevalence that causes hair loss. As per the alopecia treatment market overview, demand in the industry is rising as more individuals become aware and look for efficient treatment solutions. Therefore, people are resorting to medical aid for hair restoration due to advances in medical technology and a wide range of treatment options accessible, leading to a considerable expansion in the market for alopecia therapy.

Rising Healthcare Expenditure

The escalating healthcare expenditure worldwide is a pivotal factor driving the growth trajectory of the alopecia treatment market. Global healthcare spending increased by 21% on average in 2020, as per reports. This number has increased even further by 2021, when it was a startling 25% higher than in 2019. Moreover, the per capita health spending increased in most peer countries between 2021 and 2022. A moderate 2.9% growth in per capita health spending was reported in the US, Australia (2.4%), Canada (0.7%), and the UK (0.5%). Among the countries for whom data was available, Belgium experienced the largest growth in per capita health spending, rising 9.6% between 2021 and 2022. Notably, developed nations show an especially notable increase in healthcare spending, indicating the willingness of individuals to spend money on cutting-edge medical treatments, such as alopecia treatments. Hence, the burgeoning financial capability and enhanced disposable income allow a larger section of the population to avail themselves of the alopecia treatment options, thus contributing to the growth of the market.

Growing Aesthetic Consciousness

Furthermore, the growing emphasis on physical appearance and aesthetic consciousness among individuals globally is significantly contributing to the expansion of the alopecia treatment market. A survey conducted by the International Society of Hair Restoration Surgery (ISHRS) revealed that ISHRS members treated on average 165 surgical patients and 396 non-surgical patients. Moreover, ISHRS members performed surgical procedures between 0-199 hair restoration in 2021 by around two-thirds (65%) of ISHRS members, with an average member performing 179 procedures, while 78% of ISHRS members performed 0-19 hair restoration surgical operations. Members completed an average of 14 hair restoration surgical procedures per month in 2021. As a result, this rising figure illustrates increased self-consciousness among individuals about their appearance, which is exacerbated by social media's effect and the representation of ideal beauty standards. The need to adhere to perceived aesthetic ideals and cultural pressures has resulted in a noteworthy demand for effective hair restoration options. Consequently, the market for alopecia treatments is growing as more people look for ways to improve their physical appearance and deal with their hair loss issues.

ALOPECIA TREATMENT INDUSTRY SEGMENTATION:

Analysis by Drug Type :

Minoxidil
Finasteride
Others

Minoxidil is a commonly used medication that effectively treats alopecia in many forms. Minoxidil is a popular and easily accessible therapy option for male and female pattern hair loss. It is available over the counter in many locations. This FDA-approved drug comes in several forms, including foams and topical treatments. It slows down hair loss, stimulates hair growth, and increases blood supply to hair follicles. It is widely adopted due to its relative affordability when compared to prescription drugs and its efficacy in encouraging hair growth. For instance, as per a study by Research Gate, patients were treated with low-dose oral minoxidil (LDOM) for at least 3 months as a treatment for any type of alopecia, which offers a good safety profile to treat hair loss without any life-threatening adverse effects. Thus, the increasing number of alopecia is resulting in the adoption of minoxidil to treat alopecia, positively generating alopecia treatment market revenue.

Analysis by Indication :

Androgenic Alopecia
Alopecia Areata
Alopecia Totalis
Others

Androgenic alopecia leads the market with around 37.6% of market share in 2025. Androgenic alopecia, commonly known as male or female pattern baldness, holds the largest segment in the market. It is primarily due to the high prevalence of androgenic alopecia globally, which affects a significant portion of men and women. Additionally, the rising awareness and acceptance of treatment options, coupled with advances in therapeutic techniques such as topical treatments, oral medications, and hair transplant procedures, have further propelled the market growth. Hence key players are introducing advanced product variants to meet these needs. For instance, in February 2024, Pelage Pharmaceuticals, a clinical-stage regenerative medicine company created a novel treatment for hair loss, while announcing the completion of $16.75 million Series A fundraising. The funding will assist the development of a first-in-class treatment for androgenetic alopecia (pattern baldness) and other kinds of alopecia, including chemotherapy-induced hair loss. GV is leading the investment, which is also supported by Main Street Advisors, Visionary Ventures, and YK BioVentures. As a result, the increasing focus on aesthetic appearance and the psychological impact of hair loss has led to the rising demand for effective treatment solutions, solidifying androgenic alopecia's position in the alopecia treatment market outlook.

Analysis by Gender :

Male
Female

Female leads the market with around 59.8% of market share in 2025. The growing prevalence of alopecia in females coupled with a growing awareness and acceptance of medical treatments for hair loss are influencing the market growth. Women are seeking effective solutions for alopecia due to aesthetic concerns and the psychological impact of hair loss, leading to a significant demand for pharmaceutical and cosmetic treatments. Additionally, the expansion of product offerings specifically designed for female alopecia, including topical solutions, oral medications, and advanced therapies such as platelet-rich plasma (PRP) and low-level laser therapy (LLLT), has further propelled the growth of this segment. As per the American Academy of Dermatology (AAD) association, minoxidil is recognized as an over-the-counter medication approved by the US Food and Drug Administration (FDA) for treating female pattern hair loss (FPHL), since FPHL can be treated with medications that include 2% or 5% minoxidil. Therefore, the growing focus on female-centric marketing strategies and the rising trend of self-care and wellness among women are also contributing to the expansion of alopecia treatment market.

Analysis by Route of Administration :

Oral
Topical
Injectable

Topical segment holds the largest share, as it is widely used and accepted owing to its ease of use. Topical therapies, including minoxidil and corticosteroids, are non-invasive, can be administered directly to the afflicted area, and have fewer systemic adverse effects than oral and injectable options, and are frequently the first line of defense against hair loss. This route of administration is attributed to its popularity among patients who want quick fixes that work well without requiring physician care. According to the Cleveland Clinic, corticosteroids and other anti-inflammatory medications can be used to treat alopecia. It is rubbed topically (into the skin) as an ointment, cream, or foam, or injected into the scalp or other regions for the treatment.

Analysis by Distribution Channel :

Hospitals
Retail Pharmacies
Online Pharmacies

Hospitals lead the market with around 40.3% of market share in 2025. Hospital dominance is attributed to the extensive infrastructure and specialized medical expertise available in hospital settings, which ensure comprehensive diagnosis and tailored treatment plans for alopecia patients. Hospitals often provide a range of therapeutic options, including prescription medications, advanced medical procedures, and supportive care, making them a preferred choice for individuals seeking professional and effective alopecia management. Moreover, hospitals frequently collaborate with leading pharmaceutical companies and research institutions to offer cutting-edge treatments. Hence, the trust and reliability associated with hospital care contribute to their leading position in the alopecia treatment market.

Regional Analysis:

North America
- United States
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

In 2025, North America accounted for the largest market share of over 38.34%. The North America alopecia treatment market recent developments are marked by the robust healthcare infrastructure, increasing prevalence of alopecia, and increased awareness about available treatment options. The presence of major pharmaceutical companies and advancements in medical technology further bolster the market in this region. For instance, in June 2023, the U.S. Food and Drug Administration (FDA) announced the approval of ritlecitinib, a Janus kinase (JAK) inhibitor by Yale dermatologist Dr. Brett King, who worked with pharmaceutical company Pfizer for conducting a series of clinical trials with ritlecitinib. It is for the treatment of alopecia areata in adolescents and adults which is an oral medication under the name Litfulo. Furthermore, the growing inclination toward aesthetic procedures and a higher disposable income enable consumers to spend on treatments for hair loss, which is positively increasing the alopecia treatment demand in North America.

KEY REGIONAL TAKEAWAYS:

UNITED STATES ALOPECIA TREATMENT MARKET ANALYSIS

In 2025, United States accounted for 93.40% of the market share in North America. Alopecia treatment market in the United States is experiencing huge growth mainly because of heightened awareness about hair loss and a surge in demand for advanced treatments. Pharmaceutical therapies like oral Janus kinase (JAK) inhibitors are increasingly being sought after by people and prove the direction of advanced and effective solutions. This leaves a significant number of around 35 million males and 21 million females within the United States suffering from various forms of hair loss, resulting in an extensive patient population, as per reports. Consumer spending on personal care products also continues to drive the market; consumers increasingly search for remedies that can help improve their looks and make them feel better. At the forefront of the growth have been leading pharmaceutical companies, such as Pfizer and Eli Lilly, in their innovative treatments. Dermatologists play an important role in increasing access of patients to the treatments, but online platforms supplement the sources available to provide the patient with even more information about hair loss, thus increasing their availability.

EUROPE ALOPECIA TREATMENT MARKET ANALYSIS

The alopecia treatment market in Europe is growing significantly, as people are becoming increasingly aware and there is a need for more effective treatments. The European Commission approved LITFULO (ritlecitinib) for the treatment of severe alopecia areata in patients aged 12 years or older in 2023, which was an important development for treatment options. Europe is also home to one of the highest prevalences of hair loss worldwide, with eight of the top ten countries for hair loss being in the region. The Czech Republic, in particular, boasts the highest prevalence of baldness, with more than 40% of adult men suffering from it, as per an industry report. Such a high incidence of alopecia contributes to a significant patient population, thereby further driving demand for advanced therapies. Pharmaceutical treatments are followed by a trend of increasing non-invasive treatments, like laser therapy and stem cell treatment. The concern of personal care and self-esteem among people is making them take these treatments, hence pushing the growth in the market even more.

ASIA PACIFIC ALOPECIA TREATMENT MARKET ANALYSIS

The Asia Pacific alopecia treatment market is growing rapidly, driven by increasing disposable incomes and a growing concern for appearance. In Japan, the prevalence of alopecia areata ranges between 1.45% and 2.18%, according to a study that highlights the significant emotional and social impacts of the condition. The study then determined the self-reported mood, self-esteem, and social interaction effects as 70.2%, 55.8%, and 48.9%, respectively. Such research reminds the importance of more effective treatments that can halt both the medical and psychological aspects of hair loss. Alopecia is increasingly becoming a problem in countries such as China, Japan, and India, and this is further increasing the demand for medical as well as cosmetic solutions. Non-invasive treatments, laser therapy, are becoming popular with market players investing more in R&D to introduce innovative, culturally tailored products. Moreover, hair clinics are multiplying and e-commerce solutions are accelerating the growth of the market.

LATIN AMERICA ALOPECIA TREATMENT MARKET ANALYSIS

The Latin American market for alopecia treatment is still growing, considering the growing consumers' awareness as well as an increasing availability of treatment options. A 2023 publication by Dermatol Ther (Heidelb) states that though often under-recognized, in many ways it can affect patients' quality of life. Latin America prevalence range for alopecia areata 0.2% to 3.8%. The prevalence in Mexico is estimated between 0.2% and 3.8%, whereas in Peru, it ranges between 0.1% and 0.2%. The prevalence in Colombia was reported at 0.05% in 2018, with the proportion being greater in women. This increasing awareness of the disease, coupled with a large population of patients, is driving up the demand for advanced treatments. The rising trend in cosmetic surgery along with the consumers' preference towards natural treatments are further boosting this market. In the region, leading companies are expanding their distribution networks to accommodate these evolving needs.

MIDDLE EAST AND AFRICA ALOPECIA TREATMENT MARKET ANALYSIS

Alopecia treatment in the Middle East and Africa is increasingly done for medical and aesthetic reasons. However, no common consensus among the dermatologists on the prevalence of AA exists. For instance, according to a research article, the estimated prevalence of AA among the general population is believed to exceed 10% among more than one-third of dermatologists in Egypt, thereby providing a significant challenge to developing proper treatments. In Saudi Arabia, 42% of dermatologists estimated that the prevalence of AA was between 7-10%. The numbers above are reflective of the wide-reaching scope of alopecia, and as such, this trend is perpetually on the rise in the pharmaceuticals and non-invasive fields. Support for this market has also been increased by rising investments in healthcare, advanced technology in hair restoration, and rising emotions and social impacts of hair loss. More patients now seek key procedures there, such as hair transplants and laser treatments, in such places as South Africa and Egypt, to name only two.

COMPETITIVE LANDSCAPE:

The key players in the global market are actively engaged in several strategic initiatives to maintain their competitive edge. They are heavily investing in research and development to introduce innovative treatments and therapies that offer enhanced efficacy and fewer side effects. Additionally, these players are focusing on expanding their global presence by entering emerging markets and capitalizing on the growing demand for hair loss solutions. Collaborations and partnerships with dermatological clinics and healthcare providers are becoming increasingly common to ensure a wider distribution network. Moreover, several companies are leveraging digital marketing and e-commerce platforms to promote their products and reach a broader consumer base, emphasizing convenience and accessibility. For instance, in March 2023, Sun Pharma announced the successful acquisition of Concert Pharmaceuticals, Inc. Concert Pharmaceuticals is a late-stage clinical biopharmaceutical organization offering deuruxolitinib, an innovative deuterated oral JAK1/2 inhibitor, for the treatment of adult patients with moderate to severe alopecia areata.

The report provides a comprehensive analysis of the competitive landscape in the alopecia treatment market with detailed profiles of all major companies, including:

Aclaris Therapeutics Inc.
Cellmid Limited
Cipla Limited
Dr. Reddy's Laboratories Ltd.
GlaxoSmithKline plc
HCell Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Taisho Pharmaceutical Holdings Co. Ltd
Teva Pharmaceutical Industries Ltd.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the alopecia treatment market?

2. What is the future outlook of the alopecia treatment market?

3. What are the key factors driving the alopecia treatment market?

4. Which region accounts for the largest alopecia treatment market share?

5. Which are the leading companies in the global alopecia treatment market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Alopecia Treatment Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Drug Type

6.1 Minoxidil
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Finasteride
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Others
- 6.3.1 Market Trends
- 6.3.2 Market Forecast

7 Market Breakup by Indication

7.1 Androgenic Alopecia
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Alopecia Areata
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Alopecia Totalis
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast

8 Market Breakup by Gender

8.1 Male
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Female
- 8.2.1 Market Trends
- 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

9.1 Oral
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Topical
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Injectable
- 9.3.1 Market Trends
- 9.3.2 Market Forecast

10 Market Breakup by Distribution Channel

10.1 Hospitals
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
10.2 Retail Pharmacies
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
10.3 Online Pharmacies
- 10.3.1 Market Trends
- 10.3.2 Market Forecast

11 Market Breakup by Region

11.1 North America
- 11.1.1 United States
  - 11.1.1.1 Market Trends
  - 11.1.1.2 Market Forecast
- 11.1.2 Canada
  - 11.1.2.1 Market Trends
  - 11.1.2.2 Market Forecast
11.2 Asia-Pacific
- 11.2.1 China
  - 11.2.1.1 Market Trends
  - 11.2.1.2 Market Forecast
- 11.2.2 Japan
  - 11.2.2.1 Market Trends
  - 11.2.2.2 Market Forecast
- 11.2.3 India
  - 11.2.3.1 Market Trends
  - 11.2.3.2 Market Forecast
- 11.2.4 South Korea
  - 11.2.4.1 Market Trends
  - 11.2.4.2 Market Forecast
- 11.2.5 Australia
  - 11.2.5.1 Market Trends
  - 11.2.5.2 Market Forecast
- 11.2.6 Indonesia
  - 11.2.6.1 Market Trends
  - 11.2.6.2 Market Forecast
- 11.2.7 Others
  - 11.2.7.1 Market Trends
  - 11.2.7.2 Market Forecast
11.3 Europe
- 11.3.1 Germany
  - 11.3.1.1 Market Trends
  - 11.3.1.2 Market Forecast
- 11.3.2 France
  - 11.3.2.1 Market Trends
  - 11.3.2.2 Market Forecast
- 11.3.3 United Kingdom
  - 11.3.3.1 Market Trends
  - 11.3.3.2 Market Forecast
- 11.3.4 Italy
  - 11.3.4.1 Market Trends
  - 11.3.4.2 Market Forecast
- 11.3.5 Spain
  - 11.3.5.1 Market Trends
  - 11.3.5.2 Market Forecast
- 11.3.6 Russia
  - 11.3.6.1 Market Trends
  - 11.3.6.2 Market Forecast
- 11.3.7 Others
  - 11.3.7.1 Market Trends
  - 11.3.7.2 Market Forecast
11.4 Latin America
- 11.4.1 Brazil
  - 11.4.1.1 Market Trends
  - 11.4.1.2 Market Forecast
- 11.4.2 Mexico
  - 11.4.2.1 Market Trends
  - 11.4.2.2 Market Forecast
- 11.4.3 Others
  - 11.4.3.1 Market Trends
  - 11.4.3.2 Market Forecast
11.5 Middle East and Africa
- 11.5.1 Market Trends
- 11.5.2 Market Breakup by Country
- 11.5.3 Market Forecast

12 SWOT Analysis

12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
- 16.3.1 Aclaris Therapeutics Inc.
  - 16.3.1.1 Company Overview
  - 16.3.1.2 Product Portfolio
  - 16.3.1.3 Financials
- 16.3.2 Cellmid Limited
  - 16.3.2.1 Company Overview
  - 16.3.2.2 Product Portfolio
  - 16.3.2.3 Financials
- 16.3.3 Cipla Limited
  - 16.3.3.1 Company Overview
  - 16.3.3.2 Product Portfolio
  - 16.3.3.3 Financials
  - 16.3.3.4 SWOT Analysis
- 16.3.4 Dr. Reddy's Laboratories Ltd.
  - 16.3.4.1 Company Overview
  - 16.3.4.2 Product Portfolio
  - 16.3.4.3 Financials
  - 16.3.4.4 SWOT Analysis
- 16.3.5 GlaxoSmithKline plc
  - 16.3.5.1 Company Overview
  - 16.3.5.2 Product Portfolio
  - 16.3.5.3 Financials
  - 16.3.5.4 SWOT Analysis
- 16.3.6 HCell Inc.
  - 16.3.6.1 Company Overview
  - 16.3.6.2 Product Portfolio
- 16.3.7 Johnson & Johnson
  - 16.3.7.1 Company Overview
  - 16.3.7.2 Product Portfolio
  - 16.3.7.3 Financials
  - 16.3.7.4 SWOT Analysis
- 16.3.8 Merck & Co. Inc.
  - 16.3.8.1 Company Overview
  - 16.3.8.2 Product Portfolio
  - 16.3.8.3 Financials
  - 16.3.8.4 SWOT Analysis
- 16.3.9 Pfizer Inc.
  - 16.3.9.1 Company Overview
  - 16.3.9.2 Product Portfolio
  - 16.3.9.3 Financials
  - 16.3.9.4 SWOT Analysis
- 16.3.10 Taisho Pharmaceutical Holdings Co. Ltd
  - 16.3.10.1 Company Overview
  - 16.3.10.2 Product Portfolio
  - 16.3.10.3 Financials
- 16.3.11 Teva Pharmaceutical Industries Ltd.
  - 16.3.11.1 Company Overview
  - 16.3.11.2 Product Portfolio
  - 16.3.11.3 Financials
  - 16.3.11.4 SWOT Analysis